Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
McKesson
McKinsey
Fuji
Chubb
Argus Health
Deloitte
UBS
Federal Trade Commission

Generated: February 17, 2018

DrugPatentWatch Database Preview

Brivaracetam - Generic Drug Details

« Back to Dashboard

What are the generic sources for brivaracetam and what is the scope of brivaracetam freedom to operate?

Brivaracetam
is the generic ingredient in one branded drug marketed by Ucb Inc and is included in three NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brivaracetam has one hundred and forty-four patent family members in forty-one countries.

One supplier is listed for this compound.
Summary for brivaracetam
International Patents:144
US Patents:3
Tradenames:1
Applicants:1
NDAs:3
Suppliers / Packagers: 1
Bulk Api Vendors: 19
Clinical Trials: 30
Patent Applications: 417
Drug Prices:see low prices
DailyMed Link:brivaracetam at DailyMed
Pharmacology for brivaracetam
Mechanism of ActionEpoxide Hydrolase Inhibitors

US Patents and Regulatory Information for brivaracetam

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-004 May 12, 2016 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-002 May 12, 2016 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-001 May 12, 2016 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for brivaracetam

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,969,770 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
7,358,276 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Sign Up
6,806,287 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
6,858,740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
8,034,958 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Sign Up
7,692,028 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Sign Up
7,217,826 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for brivaracetam

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2016 Austria ➤ Sign Up PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 (MITTEILUNG) 20160118
90009-4 Sweden ➤ Sign Up PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073 20150114
C1001 France ➤ Sign Up PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
2016 00013 Denmark ➤ Sign Up PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073/001-022 20160118
2016013,C1265862 Lithuania ➤ Sign Up PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
0815 Netherlands ➤ Sign Up PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
2016013 Lithuania ➤ Sign Up PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Argus Health
Chubb
Healthtrust
Federal Trade Commission
Johnson and Johnson
Citi
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot